Navigation Links
MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
Date:1/26/2009

gies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to the development, therapeutic potential, and potential safety and efficacy of MAP Pharmaceuticals' MAP0004 product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the enrollment, conduct, completion and reporting of clinical trials, as well as risks relating to failure to achieve favorable clinical outcomes, and that MAP0004 will not be approved for commercial use by the United States Food and Drug Administration. The reader is cautioned not to unduly rely on the forward- looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2008, and available at http://edgar.sec.gov.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Cumberland Pharmaceuticals Appoints Lee Product Director
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
7. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
8. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
9. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
10. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
11. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... ... of its properties such as low carbon footprints and compostability. These properties can ... petroleum based plastics. On the basis of applications, the market for biodegradable plastics ...
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Mexico Biomedical Sensors Market - Growth, Trends & Forecasts ... The Mexico Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:8/31/2015)... , Aug. 31, 2015  For people with ... brighten their day. The biotechnology company, located in the ... one of the best potential therapies yet for people ... entitled, " Correction of Down syndrome and Edwards syndrome ... journal DNA Research . Elixirgen plans to develop ...
(Date:8/31/2015)... , Aug. 31, 2015  US-Australian drug ... NVGN ) today confirmed its comprehensive scientific review ... technology platforms in areas of unmet patient need. ... the remaining preclinical projects prior to entering into ... compounds. Acting Chief Executive Officer, ...
Breaking Biology Technology:Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Mexico Biomedical Sensors Market Report 2015-2020 2New Down syndrome therapy discovered 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... , , , , , 7.6.4 ... increment, which can be programmed as desired with every temperature , command, enables ... each cycle. , , With Long PCR, ... extension of the , elongation. , , ...
... , , , , There is ... applied to all PCR amplifications. For example, , depending on ... of the PCRs can differ from each other. Finding the optimal or the , ... , and efficient amplification of a specific target. , ...
... , , , , , ... DNA fragment using the PCR* are an everyday occurrence in the lab. For ... PCR reaction, which hinder, , or even prevent, further ... unequivocal assessment of the PCR result. In such cases, PCR , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Using Gradient PCR to determine the optimum annealing temperature. 2
(Date:8/25/2015)... and BELLEVUE, Wash. , ... in advanced robotic systems, announced today it will unveil ... ground vehicle (UGV), at the National Tactical Officers Association ... The Guardian S is the first-ever commercially ... of years of research and in-field trials and is ...
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
(Date:8/18/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) has ... Authentication & Identification Market: Focus On Modality, Motility ... report to their offering. The ... expected to grow at an estimated CAGR of ... $25 billion (approximately) by 2020 as per the ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... new study provides support for Darwin,s hypothesis that ... closely related species than those distantly related. While ... contains the strongest direct experimental evidence yet to ... extinction occurred more frequently and more rapidly between ...
... that chytridiomycosis, a rapidly spreading amphibian disease, has reached ... last area in the entire mountainous neotropics to be ... the Panama Amphibian Rescue and Conservation Project, a consortium ... rescue 20 species of frogs in imminent danger of ...
... implementation of the Global Strategy for Plant Conservation," ... Conservation (GPPC) in association with the Secretariat of ... Gardens Conservation International (BGCI). The conference is expected ... share their experiences and further the development of ...
Cached Biology News:New study supports Darwin's hypothesis on competition between species 2New study supports Darwin's hypothesis on competition between species 3Scientists find deadly amphibian disease in the last disease-free region of central America 2Scientists find deadly amphibian disease in the last disease-free region of central America 3Global strategy for plant conservation conference to take place at the Missouri Botanical Garden 2Global strategy for plant conservation conference to take place at the Missouri Botanical Garden 3